Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2004-01-05
2008-11-25
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023100, C435S320100
Reexamination Certificate
active
07455991
ABSTRACT:
Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SixTransmembraneEpithelialAntigen of theProstate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
REFERENCES:
patent: 6262245 (2001-07-01), Xu et al.
patent: 6329503 (2001-12-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2003/0045682 (2003-03-01), Afar et al.
patent: 2003/0060612 (2003-03-01), Goddard et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 0834563 (1998-04-01), None
patent: 1308459 (2003-05-01), None
patent: WO94/09150 (1994-04-01), None
patent: WO98/18489 (1998-05-01), None
patent: WO98/37093 (1998-08-01), None
patent: WO98/37418 (1998-08-01), None
patent: WO98/53071 (1998-11-01), None
patent: WO99/06548 (1999-02-01), None
patent: WO99/06550 (1999-02-01), None
patent: WO99/61469 (1999-02-01), None
patent: WO 99/62941 (1999-12-01), None
patent: WO99/62941 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/35937 (2000-06-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO 01/40276 (2001-06-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO 02/057303 (2002-07-01), None
patent: WO 02/059260 (2002-08-01), None
patent: WO 02/095010 (2002-11-01), None
patent: WO 02/102993 (2002-12-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO 03/004622 (2003-01-01), None
patent: WO 03/004623 (2003-01-01), None
patent: WO 03/009814 (2003-02-01), None
patent: WO 03/022995 (2003-03-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 2006/034488 (2006-03-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Brennan et al (Journal of Autoimmunity, 1989, vol. 2 suppl., pp 177-186).
Zimmer (Cell Motility and the Cytoskeleton, 1991, vol. 20, pp. 325-337).
Eriksson et al. (Diabetologia, 1992, vol. 35, pp. 143-147).
Boehringer Mannheim Biochemicals, 1994 Catalog, p. 93.
Abu-Threideh et al., Jun. 1998, EMBL/GENBANK/DDBJ Databases.
Abu-Threideh et al., GENBANK, (Accession No. 095034), National Library of Medicine, Bethesda MD, May 1, 1999.
Alberts et al., Molecular Biology of the Cell, 3rd edition (1994) p. 465.
Bellone et al., Immunology Today (1999) 20(10):457-462.
Bowie et al. (1990) Science 247:1306-1310.
Burgess et al. (1990) Jnl. Cell Biol. 111:2129-2138.
Cate et al., GENBANK, (Accession No. W86309), National Library of Medicine, Bethesda MD, Nov. 1998.
Database EMBL Nucleotide and Protein Sequences, Aug. 25, 1996, XP002128081, AA032221, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, Jun. 15, 1998, XP002128084, AC004969 (clone DJ1121E10), Hinxton, GB.
Database EMBL, “Human BAC clone CTB-167B5 form 7q21, complete sequence,” Jun. 17, 1998.
Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB.
Diss et al. (1998) “Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines,” FEBS Letters 427:5-10.
Dulcert et al., GENBANK, (Accession No. Y11840), National Library of Medicine, Bethesda MD, Feb. 11, 1999.
Falk et al., Nature (1991) 351:390-296.
Fu et al., EMBO Journal (1996) 15:4392-4401.
Greenberg et al., PNAS (1995) 92:3439.
Greenspan et al., (Nature Biotechnology 7:936-937 (1999)).
Grimes et al. (1998) “Electrophysiological characterization of voltage-gated Na+current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer,” Journal of Cellular Physiology 175:50-58.
Gura, Science (1997) 278:1041-1042.
Gutierrez et al. (1999) “Activation of a Ca2+-permeable cation channel by two different inducers of appoptosis in a human prostatic cancer cell line,” Journal of Physiology 517.1:95-107.
Haverstick et al. (2000) “Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+Entry1,” Cancer Research pp. 1002-1008.
Herbert et al. (The Dictionary of Immunology, Academic Press, 4th edition, 1995).
Hubert et al. (1999) PNAS USA 96(25):14523-14528.
Hunt et al., Science (1992) 255:1261-1263.
International Search Report mailed on Apr. 28, 2003, for PCT patent application No. PCT/US02/28371 filed on Sep. 6, 2002, 1 page.
Lal et al. (US Patent No. 6048970, May 1998, USPTO database sequence listing).
Lazar et al. (1988) Mol. Cell. Biol. 8(3):1247-1252.
Lepple-Wienhues et al. (1996) “K + Channels and the intracellular calcium signal in human melanoma cell proliferation,” J. Membrane Biol. 151:149-157.
Lewin, Genes VI, Oxford University Press, Inc., NY, Chapter 29, 1997.
Marino et al. (1994) “Association between cell membrane potential and breast cancer,” Tumor Biol. 15:82-89.
McClean et al., Eur. J. of Cancer (1993) 29A:2243-2248.
Muller et al., MCB (1991) 11:1785.
Nie et al. (1997) “Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel,” Cell Calcium 22(2):75-82, unknown.
Pancrazio et al. (1989) “Voltage-dependent ion channels in small-cell lung cancer cells1,” Cancer Research 49:5901-5906.
Parker et al., J. Immunol. (1994) 152:163-175.
Peshwa et al., Prostate (1998) 36:129-138.
Rama et al.. Biochem. J. 318:333-341 (1996).
Rieger et al., Glossary of Genetics and Cytogenetics, Springer-Verlag (1976) p. 17.
Shantz et al., Int. J. of Biochem. and Cell Bio. (1999) 31:107-122.
Skryma et al., (1997) “Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation,” The Prostate 33:112-122.
Spitler, Cancer Biotherapy (1995) 10:1-3.
Stewart et al., Genome Res. (1997) 7:422.
Walter et al., Nat. Genetics (1994) 7:22.
Xue et al., Prostate (1997) 30:73-78.
Challita-Eid et al., “Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication in Vitro and Growth of Human Tumor Xenografts in Vivo” Cancer Research, 61(12):5798-5805 (2007). XP002469628; ISSN: 0008-5472 (Abstract).
Faris et al., “Validation of Steap-1 as a Cell Surface Cancer Therapeutic Target” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, US. 43:947 (2002). XP001207871, ISSN: 0197-016X.
Hubert et al., “STEAP: A Prostate-Specific Cell Surface Antigen Highly Expressed in Human Prostate Tumors” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, US 96(25)14523-14528 (1999). XP00946864; ISSN: 0027-8424.
Afar Daniel E. H.
Hubert Rene S.
Mitchell Steven Chappell
Raitano Arthur B.
Saffran Douglas
Agarwal Atulya R.
Agensys, Inc.
Dreger, Esq. Ginger R.
Popp, J. D., L.L.M. Shane M.
Yu Misook
LandOfFree
Serpentine transmembrane antigens expressed in human cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serpentine transmembrane antigens expressed in human cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serpentine transmembrane antigens expressed in human cancers... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043768